AzTrials
AzTrials

Pain, PostoperativePhase 3NCT00551135

Surgical Pain After Inguinal Hernia Repair (SPAIHR)

A Phase 3 study testing Pregabalin in people with Pain, Postoperative and Hernia, Inguinal, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 6 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair. Read more about this study

Who is it for?
Ages 17 to 75 years, men only
Conditions the study is for
Pain, Postoperative, Hernia, Inguinal
What is being tested?
Pregabalin
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
425 participants
Where
42 sitesin 6 countries
Study dates
Jan 2008to Sep 2009
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 17 to 75 years
  • Men only
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • The subject will have elective ( the subject chooses, but does not have to undergo surgery for an emergency) open unilateral inguinal herniorraphy (hernia repair), using mesh Lichtenstein surgery procedure and under general anesthesia and fentanyl or sufentanil/propofol initiation and sevoflurane or isoflurane maintenance plus local anesthetic infiltration at the conclusion of surgery. Study surgery should be anticipated to be in the morning.
  • Expected to be able to use and tolerate non-steroidal anti-inflammatory drugs (such as naproxen), tramadol, oxycodone, and acetaminophen/paracetamol for pain control after surgery.
  • The subject will be available for a visit within 72 hours of the day of surgery if not admitted the night before for baseline assessments before taking any study medication, and then to receive study medication prior to the day before surgery.
  • The subject is expected and agrees to remain at the hospital (or intermediate care facility) for a minimum of 3 hours following surgery.

Who cannot join

  • Subjects with non elective or emergency surgery (must have the surgery no matter what), or hernia with incarceration (the trapping of abdominal contents within the hernia itself).
  • Subjects with hernia repair that is not a primary repair. The planned use of nerve block or spinal/epidural/paravertebral anesthesia or surgery is not planned with general anesthesia.
  • Subjects that are not allowed to receive the anesthesia agents indicated per protocol and general anesthesia.

Trial locations and contacts

42 sites in 6 countries.

42 sites in 6 countries

United States24 sites
  • Pfizer Investigational Site

    Birmingham, Alabama, 35235

  • Pfizer Investigational Site

    Columbus, Ohio, 43210

  • Pfizer Investigational Site

    Dallas, Texas, 75390-7208

  • Pfizer Investigational Site

    Durham, North Carolina, 27710

  • Pfizer Investigational Site

    Glendale, California, 91206

  • Pfizer Investigational Site

    Hermitage, Tennessee, 37075

  • Pfizer Investigational Site

    Hermitage, Tennessee, 37076

  • Pfizer Investigational Site

    Houston, Texas, 77024

  • Pfizer Investigational Site

    Houston, Texas, 77054

  • Pfizer Investigational Site

    Houston, Texas, 77091

  • Pfizer Investigational Site

    Houston, Texas, 77098

  • Pfizer Investigational Site

    Humble, Texas, 77338

  • Pfizer Investigational Site

    Kingwood, Texas, 77339

  • Pfizer Investigational Site

    Knoxville, Tennessee, 27920

  • Pfizer Investigational Site

    Knoxville, Tennessee, 37920

  • Pfizer Investigational Site

    Laguna Hills, California, 92653

  • Pfizer Investigational Site

    Lake Worth, Florida, 33462

  • Pfizer Investigational Site

    Nashville, Tennessee, 37203

  • Pfizer Investigational Site

    Pasadena, California, 91105

  • Pfizer Investigational Site

    Pensacola, Florida, 32504

  • Pfizer Investigational Site

    Pittsburgh, Pennsylvania, 15232

  • Pfizer Investigational Site

    Rochester, Minnesota, 55905

  • Pfizer Investigational Site

    Rochester, New York, 14642

  • Pfizer Investigational Site

    Stony Brook, New York, 11794-8480

Other trials in United States

Sweden5 sites
  • Pfizer Investigational Site

    Gävle, 801-87

  • Pfizer Investigational Site

    Landskrona, 261 24

  • Pfizer Investigational Site

    Mora, SE-792 85

  • Pfizer Investigational Site

    Örebro, 701 85

  • Pfizer Investigational Site

    Skellefteå, 931 86

Other trials in Sweden

Canada4 sites
  • Pfizer Investigational Site

    Charlottetown, Prince Edward Island, C1A 8T5

  • Pfizer Investigational Site

    London, Ontario, N6A 4V2

  • Pfizer Investigational Site

    London, Ontario, N6A 5A5

  • Pfizer Investigational Site

    Québec, Quebec, G1V 4G2

Other trials in Canada

India4 sites
  • Pfizer Investigational Site

    Delhi, 110 095

  • Pfizer Investigational Site

    Madurai, Tamil Nadu, 625 107

  • Pfizer Investigational Site

    Pune, Maharashtra, 411011

  • Pfizer Investigational Site

    Vadodara, Gujarat, 390001

Other trials in India

Spain4 sites
  • Pfizer Investigational Site

    Alcorcón, Madrid, 28922

  • Pfizer Investigational Site

    Barcelona, 08036

  • Pfizer Investigational Site

    Madrid, 28006

  • Pfizer Investigational Site

    Madrid, 28031

Other trials in Spain

Australia1 site
  • Pfizer Investigational Site

    Randwick, New South Wales, 2031

Other trials in Australia

About this study

Official title: A Randomized, Double Blind Multi Center Dose Ranging Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo In The Adjunctive Treatment Of Post Surgical Pain After Primary Inguinal Hernia Repair

The purpose of this study is to test whether pregabalin added to the standard of care with dosing starting preoperatively and continuing for 1 week post surgery will decrease the intensity of acute post-operative pain following inguinal hernia repair.

Being tested
Pregabalin, placebo
Keywords
postoperative pain chronic pain
Medical subject headings
Pain, Postoperative, Hernia, Inguinal

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT00551135
Study groupRoleWhat they receive
3ExperimentalNot described
Receives: Drug: Pregabalin
4Placebo comparatorNot described
Receives: Drug: placebo
2ExperimentalNot described
Receives: Drug: Pregabalin
1ExperimentalNot described
Receives: Drug: Pregabalin

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery

    m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. A single item pertains to worst pain in the past 24 hours: range of 0 (no pain) to 10 (worst imaginable pain).

    Measured: 24 hours post surgery

Secondary outcomes (26)
  1. Numeric Rating Scale (NRS): Current Pain With Movement - Sitting

    NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by sitting (sitting in a standardized fashion after being in a fully supine position); range: 0 (no pain) to 10 (worst pain).

    Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])

  2. Numeric Rating Scale (NRS): Current Pain With Movement - Walking

    NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by walking (rising from sitting position and walking approximately 5 meters or 16 feet at a moderate pace); range: 0 (no pain) to 10 (worst pain).

    Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])

  3. Numeric Rating Scale (NRS): Current Pain With Movement - Coughing

    NRS: a self-administered questionnaire to rate pain. A single item asks to rate pain with movement caused by coughing (coughing two times while sitting); range: 0 (no pain) to 10 (worst pain)

    Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, and 7 PS; and End of Treatment (EOT [Day 7 PS or Early Termination])

  4. Numeric Rating Scale (NRS): Current Pain With Movement - Area Under the Curve (AUC) for Sitting, Walking, and Coughing

    NRS: a self-administered questionnaire to rate pain. AUC from 1 h PS through 48 h PS for ratings of pain caused by movements of sitting, walking, and coughing; Range: 0 (no pain) to 10 (worst pain).

    Measured: 1 hour through 48 hours post surgery

  5. Numerical Rating Scale (NRS): Current Pain at Rest

    NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).

    Measured: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 PS

  6. Numeric Rating Scale (NRS): Current Pain at Rest - Area Under the Curve (AUC)

    NRS: a self-administered questionnaire to rate pain. AUC for a single item asking participant to rate current pain at rest (preceding pain with movement); range: 0 (no pain) to 10 (worst pain).

    Measured: 1 through 48 hours post surgery (PS)

  7. Numeric Rating Scale (NRS): Average Pain

    NRS: a self-administered questionnaire to rate pain. A single item asks participant to rate pain on average in the last 24 hours; range: 0 (no pain) to 10 (worst pain).

    Measured: 2 hours (h) before surgery (BS); 1, 2, and 3 h post surgery (PS); Days 1, 2, 3, 4, 5, 6, and 7 PS

  8. Time From End of Surgery to First Rescue Medication

    Rescue medication includes both naproxen and narcotic medication (including tramadol and opioid analgesics). For subjects without use of rescue medication, the time-to-event variable is censored at the Beginning of Taper Visit (Day 7 PS) or at time of withdrawal.

    Measured: Day 1 through Day 7 post surgery

  9. Time From End of Surgery to Reach a Total Score of at Least 9 on the Post-Anesthetic Discharge Scoring System (PADS)

    PADS is a 5-item scale (individual item range: 0-2; higher scores indicating better readiness for hospital discharge). Total score range: 0-10, with 9 or higher indicating eligibility for discharge. End of surgery is time of transfer to post-anesthesia care unit (PACU). Subjects who did not reach a score of 9 on PADS were censored at the date and time of discharge.

    Measured: Day 1

  10. Time From End of Surgery to Discharge From Post-Anesthesia Care Unit (PACU)

    Measured: Day 1

  11. Daily Sleep Interference Rating Scale (DSIRS) Score

    DSIRS: self-administered 11-point Likert scale ranging from 0 (pain does not interfere with sleep) to 10 (pain completely interferes with sleep [unable to sleep due to pain]) during past 24-hour period. Higher score indicates a greater level of sleep disturbance. Performed daily on awakening, prior to taking study medication.

    Measured: Days 2, 3, 4, 5, 6, 7, 8, 9, and 10 post surgery (PS)

  12. Total Cumulative Dose of Opioids and Tramadol Used During and After Surgery

    Total cumulative dose of opioids and tramadol administered by any route during surgery and postoperatively. Dose of tramadol calculated as milligrams (mg) of oral morphine equivalent.

    Measured: 24, 48, and 72 hours (h) post surgery (PS), and Days 4, 5, 6, and 7 PS

  13. Amount of Non-opioid Rescue Medication (Naproxen and Antiemetic Medications) Used During the Study

    Total cumulative dose of naproxen calculated in milligrams (mg) from the end of surgery up to and including Day 7 after surgery.

    Measured: End of Surgery through Day 7 post surgery

  14. Total Clinically Meaningful Event (CME) Score and Cumulative Total Distinct CME Score Using the Opioid-Related Symptom Distress Scale (OR-SDS)

    OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). The Total Distinct CME score is the sum of CMEs across symptoms (range: 0 [none] to 10 [10 CMEs]); the Cumulative Total Distinct (CT Distinct) CME score is the sum of Total Distinct CME scores at observation and prior observations. The Total CME score is the same as the Total Distinct CME score except that only 1 CME is counted if both nausea and vomiting (or retching) occur (range: 0 [none] to 9 [9 CMEs]).

    Measured: 3, 24, and 72 hours (h) Post-Surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])

  15. Participants With Clinically Meaningful Events (CMEs) for Individual Symptoms Using the Opioid-Related Symptom Distress Scale (OR-SDS)

    OR-SDS: a self-administered assessment of 10 common opioid-related side effects (symptoms). A CME is a severe or very severe symptom (or moderate or greater severity symptom of confusion). For individual symptom categories, the number of subjects who experienced at least one CME. Concentrate (concentr).

    Measured: 3, 24, and 72 hours (h) post surgery (PS), and End of Treatment (EOT [Day 7 PS or Early Termination])

  16. Subject Global Evaluation of Study Medication (GESM)

    GESM is a self-administered overall impression (global evaluation) of study medication received for pain; 4 categories: poor, fair, good, and excellent.

    Measured: 24 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])

  17. Participants With Wound Healing Complications

    Investigator-assigned mutually exclusive categories of: 1) no surgical wound complication, 2) superficial incisional surgical site infection, 3) deep incisional surgical site infection, 4) organ or space surgical site infection, or 5) non-infectious wound healing complication.

    Measured: Day 7 post surgery (PS) and up to 30 days PS

  18. Participants With Physician Contacts Post-discharge

    Number of participants who answered "yes" to the Post-Surgery Contact question: "From the time you were discharged from the hospital, did you have to contact any type of physician because of pain, difficulty getting up and walking about, or difficulty with passing urine?"

    Measured: 24 and 72 hours (h) post surgery (PS)

  19. Baseline and Change From Baseline in Anxiety Visual Analog Scale (VAS) Score

    Anxiety VAS is a single-item self-administered continuous measure of anxiety using a 100-millimeter (mm) line on which the subject is asked to place a mark indicating the intensity of current anxiety. The score is the distance in mm from the left-most point on the line to the subject's mark; range: 0 (Not at all anxious) at the left-most point to 100 (Extremely anxious) at the right-most point. Performed prior to blood draws.

    Measured: Baseline; 2 hours (h) before surgery (BS); 1, 2, and 3 h PS; Days 2, 3, 4, 5, 6, 7, 8, and 9 PS

  20. Baseline and Change From Baseline in EuroQol (EQ-5D) Health State Profile Score

    EQ-5D is a self-administered questionnaire to assess health-related quality of life in 5 domains (mobility, self care, usual activities, pain or discomfort, and anxiety or depression). Scores from the 5 domains are used to calculate a single index value: the Health State Profile Score; range: 0.0 (death) to 1.0 (perfect health), higher scores indicating better health state.

    Measured: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])

  21. Change From Baseline in Pain Catastrophizing Scale (PCS) Total Score and Subscales

    The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all questions (range: 0 to 52); Subscale scores: Rumination (sum of scores for 4 items; range: 0 to 16); Magnification (sum of scores for 3 items; range: 0 to 12); and Helplessness (sum of scores for 6 items; range: 0 to 24); higher scores mean a greater extent of pain catastrophizing.

    Measured: 3 hours (h) post surgery (PS) and End of Treatment (EOT [Day 7 PS or Early Termination])

  22. Relationship Between Baseline and Postoperative Pain Catastrophizing Scale (PCS) Score and Severity of Acute Pain and to Response to Therapy

    The PCS is a self-administered questionnaire with 13 items, each scored from 0 (not at all) to 4 (all the time) for extent to which participant catastrophizes postoperative pain. Total score is sum of scores for all items (range: 0 to 52); higher scores mean a greater extent of pain catastrophizing.

    Measured: Baseline and Days 1 and 7 post surgery (PS)

  23. Baseline and Change From Baseline in Short Form Acute Health Survey 12-Item Version (SF-12v2) Physical Component Summary Score (PCSS) and Mental Component Summary Score (MCSS)

    PCSS and MCSS are component summary scores from the self-administered SF-12v2 acute health quality of life, norm-based survey. PCSS range: 4.95 to 76.13; MCSS range: -0.79 to 79.69; lowest scores mean very much below and highest scores mean very much above the general population average.

    Measured: Baseline and End of Treatment (EOT [Day 7 post surgery or Early Termination])

  24. Participants With Chronic Postoperative Pain

    Number of participants who reported surgery-related pain at assessment (by answering 'yes' to a single question: "In the last 24 hours, have you had pain in the area affected by your surgery?")

    Measured: 1, 3, and 6 months (mo) post surgery (PS)

  25. Chronic Postoperative Pain: Pain Severity Index Score and Pain Interference Index Score on the Modified Brief Pain Inventory-Short Form (mBPI-sf)

    m-BPI-sf: a self-administered 11-point Likert rating scale to rate pain in the past 24 hours. Pain interference index score is mean of 7 individual item scores for interference of pain with functional activities (general activity, mood, walking ability, relations with other people, sleep, normal work, and enjoyment of life); range: 0 (does not interfere) to 10 (completely interferes with functional activities). Pain severity index score is mean of 4 individual item scores for pain severity (pain right now, and worst, least, and average pain); range: 0 (no pain) to 10 (worst imaginable pain).

    Measured: 1, 3, and 6 months (mo) post surgery (PS)

  26. Chronic Postoperative Pain: Total Score and Subscale Scores Using the Neuropathic Pain Symptom Inventory (NPSI)

    NPSI: a 12-item self-administered questionnaire to assess the characteristics of neuropathic pain on average in the last 24 hours. 5 subscale scores include: burning spontaneous (spont.) pain, pressing spont. pain, paroxysmal pain, evoked pain, and paresthesia or dysesthesia (paresth/dysesth) (range: 0 [no pain] to 10 [worst pain imaginable]); total score calculated from the 5 pain subscores (range: 0 to 0.5), higher scores meaning worse pain.

    Measured: 1, 3, and 6 months (mo) post surgery (PS)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 Oct 2007 (estimated)
  2. Study startJan 2008
  3. Primary completionJun 2009
  4. Study completionSep 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
425 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00551135
Sponsor's protocol ID
A0081171
Status last verified
Jun 2010
First submitted
26 Oct 2007
Last updated
25 Jan 2021
Data monitoring committee
No

Publications

  • Singla NK, Chelly JE, Lionberger DR, Gimbel J, Sanin L, Sporn J, Yang R, Cheung R, Knapp L, Parsons B. Pregabalin for the treatment of postoperative pain: results from three controlled trials using different surgical models. J Pain Res. 2014 Dec 23;8:9-20. doi: 10.2147/JPR.S67841. eCollection 2015.

    PubMed 25565885

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing Pregabalin in people with Pain, Postoperative and Hernia, Inguinal, run by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. at 42 sites in 6 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 25 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 42 sites in United States, Sweden, Canada, India, Spain and 1 more country. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 15 Jul 2010). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Modified Brief Pain Inventory-Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery (time frame: 24 hours post surgery). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00551135, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Jan 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Surgical Pain After Inguinal Hernia Repair (SPAIHR) | AzTrials